Hey everyone —
The FDA approved Zepbound (tirzepatide) on November 8, 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is the first drug approved for obesity that simultaneously targets both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor — a dual mechanism that produced the largest weight reduction ever observed in a phase 3 obesity clinical trial.
Compounds covered in this article
WHAT TIRZEPATIDE IS AND HOW IT DIFFERS FROM SEMAGLUTIDE
Semaglutide (Wegovy) acts on the GLP-1 receptor alone. Tirzepatide is engineered as a dual agonist: it binds both GLP-1 receptors and GIP receptors on a single molecular scaffold. GIP is another incretin hormone released postprandially. Its receptors are expressed in adipose tissue, and GIP signaling appears to synergize with GLP-1 to suppress appetite and mobilize fat through complementary pathways.
Tirzepatide was first approved as Mounjaro for type 2 diabetes in May 2022, making the obesity approval its second indication. The same dual mechanism that improved glycemic control also drove substantially greater weight loss than any prior GLP-1 agent — establishing tirzepatide as the class leader on efficacy.
SURMOUNT-1 RESULTS
The pivotal SURMOUNT-1 trial enrolled 2,539 adults with BMI ≥30 (or ≥27 with at least one weight-related condition) and no type 2 diabetes. Participants received tirzepatide at 5mg, 10mg, or 15mg weekly or placebo for 72 weeks. At the highest 15mg dose, participants lost a mean of 22.5% of baseline body weight versus 2.4% for placebo — a 20.1 percentage point difference.
That 22.5% figure is the largest weight reduction ever recorded in a phase 3 clinical trial for an obesity drug. Nearly 1 in 3 participants on 15mg tirzepatide lost at least 25% of their body weight — outcomes previously associated only with bariatric surgery.
COMPARISON TO SEMAGLUTIDE AND WHAT'S NEXT
The SURMOUNT-5 trial (published 2025) provided the first head-to-head randomized comparison of tirzepatide vs semaglutide 2.4mg. Result: tirzepatide 10mg or 15mg produced approximately 10 additional percentage points of mean weight loss versus semaglutide 2.4mg at 72 weeks — confirming the superiority suggested by cross-trial comparisons. The efficacy hierarchy is clear; individual tolerability, access, and cost remain determining factors.
The SURPASS-CVOT cardiovascular outcomes trial for tirzepatide has since published positive results, and the SURMOUNT-MMO trial in non-diabetic obese patients is underway, tracking MACE endpoints to establish tirzepatide's cardiovascular indication alongside its obesity approval.
Sources & References
